Wenyue Hu

发表

Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology

Shuyan Lu, B. Jessen, Dalia Kalabat, 2018, Molecular Cancer Therapeutics.

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Shibing Deng, Hui Wang, Shinji Yamazaki, 2015, Cancer cell.

Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony–Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation

M. Spilker, T. Sung, Wenyue Hu, 2020, The AAPS Journal.

PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations

M. McTigue, Sergei L Timofeevski, Qiuhua Li, 2015, Proceedings of the National Academy of Sciences.

Dose-dependent effects of small-molecule antagonists on the genomic landscape of androgen receptor binding

Zhou Zhu, A. Fanjul, P. Rejto, 2012, BMC Genomics.

Development of Highly Optimized Antibody–Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia

F. Loganzo, C. J. O’Donnell, A. Maderna, 2020, Clinical Cancer Research.

A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor

M. Spilker, Diane D. Wang, Yanke Yu, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Cardiovascular differentiation of imatinib and bosutinib in the rat

B. Jessen, A. Mcharg, J. Jamieson, 2013, International Journal of Hematology.

A tyrosine kinase inhibitor‐induced myocardial degeneration in rats through off‐target phosphodiesterase inhibition

B. Jessen, Wenyue Hu, B. Hirakawa, 2012, Journal of applied toxicology : JAT.

Transient knock down of checkpoint kinase 1 in hematopoietic progenitors is linked to bone marrow toxicity.

B. Jessen, Wenyue Hu, A. John-Baptiste, 2011, Toxicology letters.

Comparative Analyses of Poly(ADP-Ribose) Polymerase Inhibitors

Mathew P. Martin, M. Guha, Wenyue Hu, 2022, International journal of toxicology.

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies

B. Jessen, S. Thibault, Wenyue Hu, 2015, Clinical Cancer Research.

A whole‐body circulatory neutrophil model with application to predicting clinical neutropenia from in vitro studies

M. Spilker, Wenyue Hu, D. D’Argenio, 2021, CPT: pharmacometrics & systems pharmacology.

Abstract A277: PF-06463922, a novel ROS1/ALK inhibitor, demonstrates sub-nanomolar potency against oncogenic ROS1 fusions and capable of blocking the resistant ROS1G2032R mutant in preclinical tumor models.

Sergei L Timofeevski, S. Yamazaki, Qiuhua Li, 2013 .

Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance

Ping Chen, Simon Bergqvist, Xiu Yu, 2016, Molecular Cancer Therapeutics.

Liver toxicity observed with lorlatinib when combined with strong CYP3A inducers: evaluation of cynomolgus monkey as a nonclinical model for assessing the mechanism of combinational toxicity.

T. R. Johnson, X. Palazzi, Y. Pithavala, 2021, Toxicological sciences : an official journal of the Society of Toxicology.

Phenotypic Characterization of Targeted Knockdown of Cyclin-Dependent Kinases in the Intestinal Epithelial Cells.

Shuyan Lu, B. Jessen, Wenyue Hu, 2020, Toxicological sciences : an official journal of the Society of Toxicology.

Evaluation of miR-216a and miR-217 as Potential Biomarkers of Acute Exocrine Pancreatic Toxicity in Rats

W. Evering, W. Bobrowski, S. Thibault, 2017, Toxicologic pathology.

Abstract 1635: Mechanistic investigation of neutropenia associated with palbociclib

B. Jessen, Wenyue Hu, A. Sacaan, 2015 .

Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquin

K. Gajiwala, N. Sach, P. Kung, 2017, Journal of medicinal chemistry.

Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.

P. Kung, S. Yamazaki, M. Edwards, 2016, Journal of medicinal chemistry.

Design and Synthesis of Pyridone-Containing 3 , 4-Dihydroisoquinoline-1 ( 2 H ) ‐ ones as a Novel Class of Enhancer of Zeste Homolog 2 ( EZH 2 ) Inhibitors

P. Kung, S. Yamazaki, M. Edwards, 2016 .

Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase.

Shuyan Lu, B. Jessen, L. Marroquin, 2012, Toxicological sciences : an official journal of the Society of Toxicology.

Crizotinib reduces the rate of dark adaptation in the rat retina independent of ALK inhibition.

T. R. Johnson, C. Somps, Wenyue Hu, 2015, Toxicological sciences : an official journal of the Society of Toxicology.

Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901

S. Yamazaki, D. Wojciechowicz, S. Bagrodia, 2012, Molecular Cancer Therapeutics.

An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity.

Danielle E. Dettling, J. Chaparro-Riggers, Y. A. Yeung, 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

Correction to Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors.

P. Kung, S. Yamazaki, M. Edwards, 2016, Journal of Medicinal Chemistry.

Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.

M. Gleave, A. Zoubeidi, A. Fanjul, 2011, Journal of medicinal chemistry.

Gemtuzumab Ozogamicin Treatment Results in Decreased Proliferation and Differentiation of Human Megakaryocytes but Does Not Inhibit Mature Platelet Function

Wenyue Hu, A. Sacaan, A. Vitsky, 2022, Toxicologic pathology.

Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility

Zhou Zhu, S. Murphy, Sergei L Timofeevski, 2015, PloS one.

Use of the dTAG system in vivo to degrade CDK2 and CDK5 in adult mice and explore potential safety liabilities

Seda Arat, S. Thibault, Wenyue Hu, 2023, Toxicological sciences : an official journal of the Society of Toxicology.

Development of a Machine-Learning Model for Prediction of Extubation Failure in Patients with Difficult Airways after General Anesthesia of Head, Neck, and Maxillofacial Surgeries

Wenyue Hu, Ren Zhou, Ling Zhang, 2023, Journal of clinical medicine.

Abstract PR10: Is CNS availability for oncology a no-brainer? Discovery of PF-06463922, a novel small molecule inhibitor of ALK/ROS1 with preclinical brain availability and broad spectrum potency against ALK-resistant mutations.

N. Sach, M. McTigue, H. Zou, 2013 .

Abstract C253: PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.

Sergei L Timofeevski, S. Yamazaki, Qiuhua Li, 2013 .